Oligomerization and aggregation of α‐synuclein molecules are believed to play a major role
in neuronal dysfunction and loss in Parkinson's disease (PD) and dementia with Lewy …

Levodopa is the most effective medication for Parkinson's disease (PD). In contrast, there is
evidence that levodopa and its metabolites such as dopa/dopamine quinone are toxic for …

Alpha-synuclein aggregation is associated with Parkinson's disease and other
neurodegenerative disorders termed synucleinopathies. The sequence of alpha-synuclein …

Parkinson's disease (PD) is characterized by a progressive loss of dopamine (DA) neurons
of the nigrostriatal system and by the presence of Lewy bodies (LB), proteinaceous …

α-Synuclein (αS) is an amyloidogenic neuronal protein associated with several
neurodegenerative disorders. Although unstructured in solution, αS forms α-helices in the …

α-Synuclein (aS) is a protein abundant in presynaptic nerve terminals in Parkinson disease
(PD) and is a major component of intracellular Lewy bodies, the pathological hallmark of …

NO• alone is a poorly reactive species; however, it is able to undergo secondary reactions to
form highly oxidizing and nitrating species, NO2•, N2O3, and ONOO−. These secondary …

Interest in neurodegenerative disorders has increased markedly in the last several decades;
however, the exact pathological mechanisms of disorders such as Alzheimer's disease (AD) …

A critical step in Parkinson's disease (PD) is the formation of toxic α‐synuclein oligomers
(αSOs). In vitro αSOs are formed by self‐assembly of α‐synuclein at high concentrations, or …

Aggregated alpha-synuclein is the main component of Lewy bodies, intraneuronal
inclusions found in brains with Parkinson's disease and dementia with Lewy bodies. A body …